Showcasing low endotoxin LMLE at RDD Europe 2025

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE will be a high-profile presence as a leading member of the US-based Respiratory Drug Delivery forum at its annual European conference in Portugal.

MEGGLE will have a tabletop display in the Exhibition Zone at the Estoril Congress Center that will showcase its InhaLac® range of inhalation optimised milled and micronized lactose excipients, as well as its recently introduced LMLE lactose monohydrate low endotoxin variant.

Low endotoxin platform

LMLE is coarse sieved powder of exceptional microbiological purity that takes advantage of lactose’s well-known protective properties in freeze-dried (lyophilized) or spray-dried parenteral products to make it highly suitable for inhalation, ophthalmic, and parenteral applications. Lactose LE is also highly useful as a protective and bulking agent in formulations for temperature-sensitive products.

Rather than being produced to a target particle size distribution (PSD), Lactose LE is intended as ‘raw material’ for manufacturers who wish to perform milling or fractionation to their own desired particle size.

Optimized for DPI

MEGGLE will also exhibit its extensive range of InhaLac® lactose monohydrates optimized to various dry powder inhalation (DPI) applications. ranging from sieved InhaLac® 70, through more than 10 sieved, milled and fine milled grades, up to the finest micronized InhaLac® 500 grade.

For 2025, MEGGLE will be represented at RDD Europe by its Business Development Manager Excipients – Inhalation Tristan Mul, and Head of Innovation & Formulation at the Munich R&D Campus, Julia Evers.

RDD supporter

Over more than two decades, MEGGLE has been a leading supporter of the RDD Organization’s work as an international forum to discuss issues relating to pulmonary and nasal drug delivery, both as a sponsor and scientific contributor, with numerous RDD posters to its credit.

Once again, MEGGLE will use the RDD Europe conference to network with its peers and academia to keep abreast of the latest trends and developments within the respiratory medicine sphere.

About MEGGLE

Bavarian-based company MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical grade lactose, supplying the pharmaceutical industry with a broad-based and unique lactose product portfolio.

MEGGLE’s Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovation in industrial milk and whey processing. The company constantly strives to develop high-technological, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several revolutionary products, notably Tablettose®, the world’s first agglomerated pharmaceutical lactose grade for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on powdered cellulose and lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using Hypromellose and lactose for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

About RDD Europe 2025

The Respiratory Drug Delivery (RDD) series of conferences impact regulatory and scientific policies worldwide and are recognized as among the premier international meetings in this therapeutic area.

The success of the Respiratory Drug Delivery (RDD) Conference series is founded on the selection of internationally renowned speakers, lively audience participation, and the financial support of organizations with focus on all aspects of pulmonary and nasal drug delivery.

RDD 2025 will be a four-day event opening May 6, 2023, at the Estoril Congress Centre in southern Portugal, with the RDDOnline dimension providing access to content through to end of June.

Apart from an array of expert speakers, the event will include Knowledge Spaces that organize scientific content by theme so that related presentations, posters and company exhibits are together online, table top exhibitions, discussion sessions and workshops, networking events and the RDD VCU Peter R. Byron Graduate Student Award presented to the highest quality research.

The event is organized by RDDOnline with further information at: https://www.rddonline.com

Resources

Click on MEGGLE at RDD Europe 2025 to connect with MEGGLE via the event
Click on MEGGLE Milled lactose for pulmonary and nasal drug delivery for further information
Click on MEGGLE Lactose Monohydrate Low Endotoxin (LE) to learn more